We aim to describe our experience with the four-factor prothrombin complex concentrates (4F-PCC) Kcentra 1 at differing doses in patients with liver cirrhosis requiring emergent hemostasis in the setting of major or life-threatening bleeding. An automated query of patients who
Introduction
Coagulopathy of chronic liver disease (CCLD) is characterized by decreased levels of both naturally occurring anticoagulants and procoagulants, causing an imbalance of hemostasis. [1] [2] [3] [4] This imbalance increases the risk of bleeding and paradoxically the risk of thrombotic events. Fresh frozen plasma (FFP) is considered the typical choice for the reversal of CCLD, although evidence regarding efficacy is limited. 5, 6 Recent studies of recombinant factor VIIa (rFVIIa) in CCLD did not demonstrate clinically significant reversal of bleeding, decreased morbidity, or mortality. 4 Some studies suggest that the use of rFVIIa increases the incidence of thrombotic events. 7, 8 Four-factor prothrombin complex concentrates (4F-PCC) consists of vitamin K-dependent clotting factors II, VII, IX, X and proteins C and S. 9 Multiple 4F-PCC formulations are available internationally; Kcentra 1 is the 4F-PCC recently made available in the United States. Emergent reversal of oral vitamin K antagonists in the setting of acute life-threatening hemorrhage or need for invasive life-saving procedures is the main use of 4F-PCC, and Kcentra has been found to result in more rapid international normalized ratio (INR) reversal and recovery of coagulation factors than FFP when used for this indication. 10 The use of 4F-PCC to reverse coagulopathy for similar indications in patients with liver cirrhosis is not well described in the literature. Historically, PCCs were associated with high risk of thrombotic events. However, newer 4F-PCC agents exhibit a lower risk of thrombosis due to inactivation and inclusion of coagulation inhibitors and may be attractive agents to consider in patients with cirrhosis having lifethreatening bleeding. 11, 12 The aim of this case series is to describe our experience with the 4F-PCC Kcentra at differing doses in patients with liver cirrhosis needing emergent attainment of hemostasis for major life-threatening bleeding and highlight for the reader clinical considerations that may make Kcentra an attractive alternative to FFP in these cases.
Methods
We used an automated query of our institution's electronic medication administration record to identify all patients who received Kcentra between January 2014 and March 2016. Each chart was then evaluated for the indication for Kcentra administration. Patients who had clinically significant bleeding and received Kcentra for treatment of CCLD were included in the study. We considered CCLD to be the presence of liver cirrhosis and INR above 1.5. Patients who received any form of oral anticoagulation were excluded from our study.
Baseline patient demographics, indication for factor administration, laboratory values of prothrombin time (PT)/INR, hemoglobin, hematocrit, and platelets were collected for 24 hours pre-and post-Kcentra administration. Other reversal therapies such as phytonadione and blood products administration were collected.
Results
Four patients met inclusion for analysis. One patient presented with hemopericardium, cardiac tamponade, and shock and 3 patients with intracranial hemorrhage.
Case 1
The patient is a 55-year-old male with history significant for nonalcoholic steatohepatitis cirrhosis, coronary artery disease, and end-stage renal disease on dialysis. He was admitted for a nonhealing heel ulcer with osteomyelitis complicated by bacteremia requiring below-the-knee amputation. Throughout his prolonged hospital stay, he had no issues of acute coagulopathy until hospital day 57 when he was transferred to the intensive care unit (ICU) for hypoxemia and was noted to have INR of 2.0 (refer to Table 1 ).
On hospital day 60, the patient noted abdominal pain before developing shock and lactic acidosis requiring fluid resuscitation and vasopressors. Echocardiography demonstrated a 20 Â 18 Â17 mm pericardial effusion with signs of tamponade. The patient's INR of 7.3 precluded emergent treatment of cardiogenic shock by pericardiocentesis prior to INR normalization. The patient received 1 unit of FFP and after consultation with hematology was administered 50 units/kg of Kcentra and 10 mg of intravenous (IV) phytonadione with improvement in INR to 1.7 in <80 minutes. Pericardiocentesis and drain placement at that time yielded 700 mL of hemorrhagic fluid and resolution of shock. Over the next 48 hours, his pericardial drain output decreased to the point of allowing drain removal. Echocardiography at 24 and 48 hours after the pericardiocentesis showed resolution of cardiac tamponade with no effusion reaccumulation. The patient was transferred to the surgical floor on hospital day 63 and discharged to a long-term care facility on hospital day 71.
Case 2
The patient is a 53-year-old male with history of alcoholic cirrhosis, hypertension, and type II diabetes mellitus who presented with fatigue, hyponatremia, and acute-on-chronic kidney disease. Due to worsening renal function and concerns for hepatorenal syndrome, he was initiated on intermittent hemodialysis on hospital day 6. He tolerated dialysis well other than intermittent reports of minor bleeding at the dialysis catheter site with INR values between 1.6 and 2.2 (refer to Table 2 ).
On the day of anticipated discharge (hospital day 15), he developed acute-onset aphasia, and neuroimaging revealed a 15.3-mL left parieto-occipital intracerebral hemorrhage (ICH). At that time, his INR was 2.2 and platelet count was 23 (1000/mL). He received 10 mg of IV phytonadione, 2 units of FFP, and 2 units of platelets with repeat INR of 2.0. At that point, 25 units/kg of Kcentra was administered with repeat INR of 1.5, sixty minutes after infusion. Repeat computed tomography (CT) of the brain 6 and 12 hours after Kcentra showed no further expansion of the hematoma, and subsequent INR values remained at 1.5. Unfortunately, his course was further complicated by acute respiratory distress syndrome that was attributed to repeated blood product transfusion. He died 5 days after ICH from severe septic shock and multisystem organ failure.
Case 3
The patient is a 66-year-old male with history of alcoholic liver cirrhosis, esophageal varices treated by transjugular intrahepatic portosystemic shunt, and gastrointestinal bleeding due to colonic arteriovenous malformations who presented to the emergency department with acute altered mental status and an acute-on-chronic 1.3-cm-thick left subdural hematoma. He had been admitted 3 weeks prior for evacuation of an acute subdural hematoma causing brain compression and altered mental status. After the procedure, his mental status had returned to baseline. In the emergency department, the patient received 2 platelet transfusions for platelet count of 67 (1000/mL), 5 mg IV phytonadione, and 12.5 units/kg Kcentra for INR 1.6. Ten minutes after infusion of Kcentra, the INR value was 1.4 and repeat CT brain at 12 hours showed no subdural hematoma expansion. The patient required no surgical intervention and was discharged on hospital day 12 after return to baseline mental status. Computed tomography brain 2 weeks later showed unchanged subdural hematoma (refer to Table 3 ).
Case 4
The patient is a 46-year-old male with history of alcoholic liver cirrhosis and end-stage renal disease on hemodialysis who presented to the emergency department from a long-term acute care facility with bleeding from his dialysis catheter. The patient was admitted and had dialysis on hospital day 1 after which he developed hypotension and encephalopathy for which he was transferred to the ICU. He was treated with fluid resuscitation and broad-spectrum antibiotics. On hospital day 3, he had improved sufficiently for transfer to the medical floor. On hospital day 7, he returned to the ICU after acute onset altered mental status. A CT of the brain showed a <1 mL right lobar ICH (refer to Table 4 ). His laboratory studies were significant for INR of 5.9, partial thromboplastin time (PTT) of 105 seconds, and platelet count of 12 (1000/mL). He was treated with 2 units of platelets, 2 units of FFP, and 10 mg of IV phytonadione with improvement in INR to 3.6 and platelet count to 69 (1000/mL). Repeat CT scans at 5, 12, 19, and 29 hours after ICH onset demonstrated gradual sequential increase in hematoma volume and worsening neurologic examination, despite ongoing blood product transfusion. On hospital day 10, repeat imaging showed hematoma volume had increased to 10.9 mL with an INR of 3.0. At that time, 30 units/kg of Kcentra was administered with improvement in INR to 1.8, two hours after infusion. Although no further neuroimaging was performed, the patient's neurologic examination stabilized until hospital day 13 when he acutely developed fixed, dilated pupils consistent with brain herniation. He progressed to cardiac death on hospital day 14.
Discussion
Coagulopathy of chronic liver disease is characterized by an unbalanced and decreased production of procoagulant and anticoagulant factors in the setting of chronic liver disease that predisposes patients to a paradoxically increased risk of bleeding and thrombosis. 4, 13 Dysfibrinogenemia, platelet dysfunction, and an elevated von Willebrand Factor (vWF) also contributes to an impaired hemostatic function in this patient population. 14, 15 Our case series suggests that Kcentra may be an effective therapeutic option in response to life-threatening hemorrhage in patients with CCLD. Each of our cases experienced improved INR and at least a period of clinical hemostasis after Kcentra administration without complications referable to Kcentra.
Laboratory indices of coagulation such as PT/INR and PTT are commonly prolonged in CCLD. These indices poorly correlate with risk of bleeding, have not been validated in patients with cirrhosis, and take into consideration only changes in the procoagulant proteins. 13 Thrombocytopenia, hypofibrinogenemia, and elevated D-dimer are not unusual in these patients as well, which further complicates the analysis of the degree of reversal necessary to achieve hemostasis. 16 Currently, there is no universally accepted agent to rapidly and effectively treat bleeding in CCLD. Patients are administered red blood cells and platelet transfusions to correct anemia or thrombocytopenia. Phytonadione, while typically administered, is unlikely to be beneficial alone due to delayed onset of action up to 12 hours. Administration of cryoprecipitate to augment levels of fibrinogen, vWF, factor VIII, and factor XIII may be of benefit. 13 Fresh frozen plasma is generally administered as 10 to 20 mL/kg in an attempt to achieve more rapid hemostasis than can be achieved with phytonadione alone. However, the data supporting the efficacy of FFP in CCLD are limited. 5 Initial studies investigating the use of FFP in CCLD date back to the 1970s and have demonstrated varying efficacy in the role of FFP in the reversal of CCLD. 5 Most of the evidence supporting the use of FFP in CCLD stems from observational or retrospective data. Although there are no prospective clinical trials or guidelines that support the use of FFP in CCLD, clinicians routinely use FFP to attain hemostasis in unstable critically ill patients with limited evidence to support this practice. 6 Clinicians should be aware although no clinical trial that supports the use of FFP in CCLD; however, there are data suggesting increased morbidity and mortality with use of FFP in this patient population.
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Although clinicians may attempt to use lower volumes of FFP to minimize complications while correcting CCLD, initial doses up to 20 mL/kg may be required for coagulopathy correction. 17, 18 The use of such large volumes may lead to increased portal vein pressure, exacerbating liver malperfusion and worsening of coagulopathy. Additionally, the typical dose of FFP for coagulation correction presents risks of lifethreatening fluid overload and cardiopulmonary failure, particularly in patients with cirrhosis prone to volume overload, transfusion reaction-associated acute lung injury, and transfusion-related thrombotic complications. 6, 10, 19 Other limitations of FFP include administration delay related to the requirement of thawing at room temperature, risk of blood-borne infections, and data suggesting time to effect is in the range of hours. 10, 15, 16 These disadvantages of FFP relative to Kcentra have already resulted in Kcentra being considered the preferred agent for vitamin K antagonist-related coagulopathies.
Thirteen studies have investigated rFVIIa for the reversal of CCLD. Five studies investigated rFVIIa for gastrointestinal bleeds in CCLD and 4 studies each for the reversal of coagulopathy prior to an invasive procedure and prior to liver transplant. 20 The dosage range of rFVIIa was from 20 to 120 mg/kg, and results were inconsistent. At best, rFVIIa decreased the amount of blood lost without significant increase in the risk of thrombosis but did not benefit mortality. 21 Select and judicious use of rFVIIa has largely replaced the routine use of this agent. 7, 9, 19, 20, 22 A formulation of 4F-PCC other than Kcentra for the treatment of CCLD prior to urgent surgery or invasive procedure was first described by Lorenz et al in 22 patients who were administered an average of 25 units/kg prior to procedures. 2 Although the investigators did not measure PT/INR values, the correction percentage of factors of II, VII, IX, and X, protein C, and Quick's Value were measured prior to and after the administration of 4F-PCC; all factors increased significantly without apparent thrombotic complications.
2 Three other studies investigated the efficacy of 4F-PCC formulations other than Kcentra (albeit still a 4F-PCC) in patients with CCLD; one study as a reversal prior to liver transplant and two for rapid reversal in life-threatening bleeds. 1, 10, 23 All 3 studies used formulations of 4F-PCC at a dose of 25 units/kg and concluded that 4F-PCC is safe and effective for the emergent treatment of CCLD when FFP or vitamin K is not an option or fails. 1, 10, 23 Although these studies demonstrated the applicability and successful use of 4F-PCC, they were limited in that there was no comparative treatment, namely FFP.
Kwon et al recently published a retrospective cohort study in which they described their institutional experience in the reversal of CCLD with FFP, rVIIa, and 4F-PCC. 24 The authors reported that the use of 4F-PCC achieved a rapid and effective reversal of the INR with 1 case of central line thrombosis. Coagulopathy of chronic liver disease is not the only condition in which Kcentra has been used off label; Kcentra has been described both with and without concurrent FFP for the reversal of target-specific oral anticoagulants, specifically rivaroxaban and apixaban, with evidence limited to animal studies, in vitro studies, and case reports. 16, 20, 21 Our case series supports the findings of Kwon et al in that 4F-PCC (Kcentra) is an effective and safe alternative to FFP for the treatment of CCLD. Our case series is unique in that we administered Kcentra using an INR-based dosing formula adopted from vitamin K antagonist reversal dosing of Kcentra rather than a fixed dose regardless of INR. Data suggest that response to Kcentra is optimal when the INR is above 2.0. It is unclear if using doses of Kcentra less than the recommended 25 units/kg as an off-label use is as efficacious when the INR is less than 2.0. In case #3, we used 12.5 units/kg Kcentra to treating a mildly elevated INR of 1.6, with a resulting INR reduction to 1.4. It is difficult to discern the reason for the modest INR change though possibilities could include a proportionate doseresponse or diminished Kcentra efficacy below INR 2.0. In response to radiographic evidence and the patient's worsening clinical examination, we opted for a cautious approach of reduced dose Kcentra to attempt to optimize INR while minimizing adverse drug effects.
Conditions where Kcentra has been used off-label, including CCLD and reversal of the target-specific oral anticoagulants, are infrequent but important causes of life-threatening bleeding. The infrequency and acuity of these situations represent challenges to performing randomized controlled clinical trials or comparative studies of Kcentra versus other agents but also opportunities for further investigation. Our study is limited by its retrospective case series methodology and therefore an inability to directly compare a strategy of coagulopathy treatment with Kcentra only versus FFP only. We attempt to provide data that Kcentra may be a reasonable treatment option to consider in addition to FFP and that INR-guided dosing of Kcentra, like FFP, could be considered. Although one may consider the concomitant use of FFP and 4F-PCC in succession a limitation, it may be reasonable to use the more rapid acting Kcentra as an immediate reversal strategy for a life-threatening coagulopathy while FFP may be considered after Kcentra for maintenance of hemostasis in conjunction to phytonadione. 25 In addition, while FFP decreases INR values, it does so in an unpredictable unreliable manner that is delayed compared to Kcentra. Thus, although concomitant administration may occur, the effect of FFP is not likely to be realized for hours while Kcentra's effect is likely more immediate. 10, 25 Additionally, while laboratory indices of coagulation such as PT/INR and PTT are in wide spread clinical use and commonly prolonged in CCLD, these indices may not be as representative of coagulation function in CCLD as they are in nonliver disease patients. These indices poorly predict bleeding risk in CCLD and have not been validated in patients with cirrhosis. 13 The use of thromboelastography and thromboelastometry in liver disease may provide the clinician a more detailed assessment of clot formation, strength, and clot lysis than traditional markers such as INR. The role of these advanced clotting assessments in liver disease is an area of active research. 26 The optimal dose of Kcentra to treat hemorrhage in CCLD is unknown. Most studies of 4F-PCC in the literature treating vitamin K antagonist coagulopathy used an INR level driven dosing algorithm similar to our approach to CCLD. Although we did not have a case in which 4F-PCC was redosed, as has been recommended in treatment of anticoagulant-related hemorrhage that continues after initial dosing, we feel that redosing could be considered in the appropriate clinical context. 27 The prothrombin complex concentrate in the reduction of blood loss during orthotopic liver transplantation (PRO-TON) trial, which is investigating the use of 4F-PCCs to decrease blood loss during liver transplantation, may provide insights into the use of 4F-PCC in patients with cirrhosis. 28 
Conclusion
Kcentra may be a safe, effective, and rapid treatment option to be considered for hemorrhagic emergencies associated with CCLD, particularly when there are concerns for cardiopulmonary complications related to FFP dosing. Further research is needed to determine the ideal monitoring and dosing regimen for use in CCLD.
